- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00326105
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders (PEARL)
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment (PEARL STUDY)
The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to an antidepressant treatment.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Anticipato)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti
- Research Site
-
-
California
-
El Centro, California, Stati Uniti
- Research Site
-
Irvine, California, Stati Uniti
- Research Site
-
Oceanside, California, Stati Uniti
- Research Site
-
San Diego, California, Stati Uniti
- Research Site
-
-
Colorado
-
Pueblo, Colorado, Stati Uniti
- Research Site
-
-
Florida
-
Coral Springs, Florida, Stati Uniti
- Research Site
-
Deland, Florida, Stati Uniti
- Research Site
-
Gainsville, Florida, Stati Uniti
- Research Site
-
Hialeah, Florida, Stati Uniti
- Research Site
-
Jacksonville, Florida, Stati Uniti
- Research Site
-
Miami, Florida, Stati Uniti
- Research Site
-
Orlando, Florida, Stati Uniti
- Research Site
-
West Palm Beach, Florida, Stati Uniti
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti
- Research Site
-
Roswell, Georgia, Stati Uniti
- Research Site
-
-
Illinois
-
Hoffman Estates, Illinois, Stati Uniti
- Research Site
-
Naperville, Illinois, Stati Uniti
- Research Site
-
Oak Brook, Illinois, Stati Uniti
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti
- Research Site
-
Lafayette, Indiana, Stati Uniti
- Research Site
-
Valparaiso, Indiana, Stati Uniti
- Research Site
-
-
Kansas
-
Prairie Village, Kansas, Stati Uniti
- Research Site
-
Wichita, Kansas, Stati Uniti
- Research Site
-
-
Louisiana
-
Shreveport, Louisiana, Stati Uniti
- Research Site
-
-
Maryland
-
Glen Burnie, Maryland, Stati Uniti
- Research Site
-
-
Massachusetts
-
Braintree, Massachusetts, Stati Uniti
- Research Site
-
Springfield, Massachusetts, Stati Uniti
- Research Site
-
-
Michigan
-
Clinton Township, Michigan, Stati Uniti
- Research Site
-
Kalamazoo, Michigan, Stati Uniti
- Research Site
-
Royal Oak, Michigan, Stati Uniti
- Research Site
-
-
Missouri
-
St Charles, Missouri, Stati Uniti
- Research Site
-
St. Louis, Missouri, Stati Uniti
- Research Site
-
-
New Jersey
-
Cherry Hill, New Jersey, Stati Uniti
- Research Site
-
Clementon, New Jersey, Stati Uniti
- Research Site
-
-
New York
-
Cedarhurst, New York, Stati Uniti
- Research Site
-
New York, New York, Stati Uniti
- Research Site
-
Olean, New York, Stati Uniti
- Research Site
-
Rochester, New York, Stati Uniti
- Research Site
-
Staten Island, New York, Stati Uniti
- Research Site
-
-
Ohio
-
Beechwood, Ohio, Stati Uniti
- Research Site
-
Toledo, Ohio, Stati Uniti
- Research Site
-
-
Oklahoma
-
Norman, Oklahoma, Stati Uniti
- Research Site
-
Oklahoma City, Oklahoma, Stati Uniti
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti
- Research Site
-
-
Rhode Island
-
Lincoln, Rhode Island, Stati Uniti
- Research Site
-
-
South Carolina
-
Columbia, South Carolina, Stati Uniti
- Research Site
-
-
Tennessee
-
Memphis, Tennessee, Stati Uniti
- Research Site
-
-
Texas
-
Friendswood, Texas, Stati Uniti
- Research Site
-
Houston, Texas, Stati Uniti
- Research Site
-
San Antonio, Texas, Stati Uniti
- Research Site
-
Wichita Falls, Texas, Stati Uniti
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti
- Research Site
-
-
Virginia
-
Arlington, Virginia, Stati Uniti
- Research Site
-
Richmond, Virginia, Stati Uniti
- Research Site
-
-
Washington
-
Bellevue, Washington, Stati Uniti
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patient is able to provide written informed consent before beginning any study related procedures
- Patient has a documented clinical diagnosis of major depressive disorder
- Patient is able to understand and comply with the requirements of the study, as judged by a study investigator
Exclusion Criteria:
- Patients with a history of non-compliance as judged by the study investigator
- Patients with a known lack of response to previous treatment with quetiapine
- Patients who have participated in a clinical trial within 4 weeks of randomization
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
|---|
|
To evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in MDD patients with inadequate response to an antidepressant treatment as assessed by the change from randomization to week 6 in the MADRS
|
Misure di risultato secondarie
Misura del risultato |
|---|
|
To evaluate if quetiapine SR in combination with an antidepressant improves health-related quality of life of patients with MDD, compared to an antidepressant alone
|
|
To evaluate if quetiapine SR in combination with an antidepressant reduces anxiety symptoms in patients with MDD, compared to an antidepressant alone
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- McIntyre RS, Gorwood P, Thase ME, Liss C, Desai D, Chen J, Bauer M. Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder. J Clin Psychopharmacol. 2015 Dec;35(6):706-10. doi: 10.1097/JCP.0000000000000416.
- Weisler R, Montgomery SA, Earley WR, Szamosi J, Eriksson H. Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies. J Clin Psychiatry. 2014 May;75(5):520-7. doi: 10.4088/JCP.13m08624.
- Weisler R, McIntyre RS, Bauer M. Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. Expert Rev Neurother. 2013 Nov;13(11):1183-200. doi: 10.1586/14737175.2013.846519.
- Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol. 2014 Jan;29(1):16-25. doi: 10.1097/YIC.0000000000000011.
- Clayton AH, Locklear JC, Svedsater H, McIntyre RS. Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. CNS Spectr. 2014 Apr;19(2):182-96. doi: 10.1017/S1092852913000631. Epub 2013 Sep 25.
- Bauer M, McIntyre RS, Szamosi J, Eriksson H. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy. Int J Neuropsychopharmacol. 2013 Sep;16(8):1755-65. doi: 10.1017/S146114571300031X. Epub 2013 May 14.
- Vieta E, Bauer M, Montgomery S, McIntyre RS, Szamosi J, Earley WR, Eriksson H. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2013 Sep 5;150(2):639-43. doi: 10.1016/j.jad.2013.01.052. Epub 2013 Mar 14.
- El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010 Aug;13(7):917-32. doi: 10.1017/S1461145710000015. Epub 2010 Feb 23.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- D1448C00006
- PEARL
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .